|

Panitumumab IRDye 800 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Early 1: 1

Top Sponsors

  • Vanderbilt-Ingram Cancer Center1

Indications

  • HNSCC,Larynx, Pharynx and Oral Cavity1
  • HNSCC1
  • SCC - Squamous Cell Carcinoma1
  • Cancer1

Nashville, Tennessee1 trial

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Vanderbilt University Medical Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.